AI-Designed COVID Vaccine Passes First Human Trial
The needle-free DNA shot was safe in 39 volunteers and triggered immune responses to SARS-CoV-2, SARS and related bat viruses.
- Researchers at the University of Cambridge and DIOSynVax developed an AI-designed 'super-antigen' vaccine offering protection against entire families of viruses rather than just specific strains.
- Artificial intelligence analyzed genetic codes from various coronaviruses to identify essential, unchanging elements across virus families, creating a 'fundamentally new' approach that future-proofs against mutations.
- A phase I trial in Cambridge and Southampton involving 49 healthy volunteers aged 18 to 50 confirmed the vaccine is safe and triggered immune responses against SARS-CoV-2, SARS, and related bat viruses.
- More than 200 individuals will be recruited for a forthcoming phase II study, with Professor Jonathan Heeney calling the technology a 'game changer' for vaccine development.
- Scientists are now exploring applications for other virus families, including Ebola and bird flu, aiming to prevent pandemics before they start and potentially save millions of lives.
109 Articles
109 Articles
New AI-developed vaccine could protect against mutations and thousands of viruses
Cambridge researchers used AI to design a 'universal vaccine' that may protect against thousands of viruses and future mutations; first human trial found it safe and able to trigger immune response, raising hopes for pandemic prevention
AI-designed universal vaccine clears first human trial, targets future coronavirus threats with needle-free delivery
The first human clinical trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has shown that the vaccine is safe and has no significant side effects.
Researchers at the University of Cambridge have tested an AI-developed vaccine on humans for the first time – it is intended to protect against entire virus families.
AI-designed coronavirus vaccine shows promise in early human trial
London, June 7 (SANA) Scientists at the University of Cambridge have developed an AI-designed broad-spectrum coronavirus vaccine that demonstrated encouraging safety and immune responses in an early human trial, a development researchers say could strengthen preparedness for future pandemics. According to ScienceDaily, the vaccine, developed in collaboration with Cambridge-based biotechnology company DIOSynVax, was tested on 39 healthy volunteer…
Medical science has taken a historic step in the prevention of global health crises, as a team of researchers from Cambridge University developed a “essentially new” vaccine using artificial intelligence (AI). This drug promises to act proactively against all known variants of the coronavirus and anticipate future mutations before they jump from animals to humans.
A team of British researchers, led by scientists from the Universities of Cambridge and Southampton in the United Kingdom, has developed the first vaccine, completely developed by artificial intelligence, to be tested on humans.
Coverage Details
Bias Distribution
- 41% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
